BidaskClub lowered shares of Clovis Oncology (NASDAQ:CLVS) from a sell rating to a strong sell rating in a research note published on Friday morning.

CLVS has been the topic of several other reports. SunTrust Banks increased their price objective on Clovis Oncology to $90.00 and gave the company a buy rating in a research note on Monday, April 9th. Credit Suisse Group set a $86.00 price objective on Clovis Oncology and gave the company a buy rating in a research note on Thursday, April 26th. Royal Bank of Canada upgraded Clovis Oncology from a sector perform rating to an outperform rating and set a $81.00 price objective on the stock in a research note on Thursday, February 22nd. Cann started coverage on Clovis Oncology in a research note on Friday, March 23rd. They issued a hold rating on the stock. Finally, ValuEngine cut Clovis Oncology from a sell rating to a strong sell rating in a research note on Tuesday, May 22nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average price target of $84.53.

Shares of Clovis Oncology opened at $42.77 on Friday, according to MarketBeat.com. The firm has a market capitalization of $2.30 billion, a PE ratio of -8.35 and a beta of 0.94. The company has a debt-to-equity ratio of 0.92, a quick ratio of 5.74 and a current ratio of 6.55. Clovis Oncology has a 12-month low of $41.31 and a 12-month high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.18). The company had revenue of $18.50 million during the quarter, compared to analyst estimates of $18.34 million. Clovis Oncology had a negative net margin of 545.80% and a negative return on equity of 79.02%. The firm’s revenue was up 164.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.33) earnings per share. analysts anticipate that Clovis Oncology will post -5.42 earnings per share for the current year.

In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction on Monday, April 9th. The stock was sold at an average price of $60.02, for a total value of $270,090.00. Following the sale, the director now directly owns 7,618 shares in the company, valued at $457,232.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.20% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Ladenburg Thalmann Financial Services Inc. raised its stake in Clovis Oncology by 5,000.0% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,550 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,500 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Clovis Oncology in the first quarter valued at $146,000. Summit Trail Advisors LLC grew its holdings in shares of Clovis Oncology by 4,092.7% during the first quarter. Summit Trail Advisors LLC now owns 249,258 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 243,313 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Clovis Oncology by 66.6% during the first quarter. LPL Financial LLC now owns 5,461 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 2,184 shares during the last quarter. Finally, US Bancorp DE grew its holdings in shares of Clovis Oncology by 819.2% during the first quarter. US Bancorp DE now owns 5,589 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 4,981 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.